Renal Cell Carcinoma: Achieving Complete Response Renal Cell Carcinoma: Achieving Complete Response
"One of the most gratifying patient experiences that I ' ve had," says Sandy Srinivas in recounting a patient with RCC who achieved a complete response.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2022 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Kidney cancer drug set to treat heart attack patients after study found it boosted recovery by 75%
The drug, aldesleukin, stops irreversible damage to the heart following an attack by preventing harmful scar tissue from forming. It could be available to NHS patients within five years. (Source: the Mail online | Health)
Source: the Mail online | Health - January 29, 2022 Category: Consumer Health News Source Type: news
Find Individuals That Inspire You Find Individuals That Inspire You
Eric Jonasch, MD, reflects on the impact that his mentor had on his philosophy and approach to the treatment of patients with renal cell carcinoma.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 21, 2022 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Unmet Needs in the Era of Precision Medicine for RCC Unmet Needs in the Era of Precision Medicine for RCC
Sandy Srinivas, MD, examines the current unmet needs for patients with renal cell carcinoma and discusses how the KEYNOTE-564 trial can help identify the right patient for the right therapy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 20, 2022 Category: Consumer Health News Tags: None MDAngle Source Type: news
SABR With Pembrolizumab Benefits Oligometastatic Kidney Cancer SABR With Pembrolizumab Benefits Oligometastatic Kidney Cancer
The combination of stereotactic ablative body radiotherapy and a short-course of pembrolizumab is well tolerated and provides excellent local control of oligometastatic renal-cell carcinoma.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - December 30, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news
Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)
Marks Allarity’s first regulatory application for marketing approval for one of its prioritized oncology pipeline programs
NDA is supported by Allarity’s previously-filed pre-market approval (PMA) submission to the FDA for the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 22, 2021 Category: Drugs & Pharmacology Source Type: news
Somalia: Doctors Save Life of 5-Year-Old Somali Girl - Conduct Complex Kidney Tumor Surgery
[Dalsan Radio] A 5-year-old Somali girl, who was suffering from Wilm's tumour, a very rare type of kidney cancer has been successfully been treated by a team of Oncologists in India. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 9, 2021 Category: African Health Source Type: news
Novel Agent May Be Game-Changer in Rare Genetic Disease Novel Agent May Be Game-Changer in Rare Genetic Disease
Patients with von Hippel-Lindau face a high risk of renal cell carcinoma and other cancers, which often require multiple surgeries. A new drug may change the course of the disease.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 1, 2021 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news
FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer FDA Nod for Adjuvant Pembrolizumab in Kidney Cancer
This is the first immunotherapy to be approved for adjuvant use in intermediate- or high-risk patients with renal cell carcinoma after surgery.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
Keytruda Is Now Approved for the Adjuvant Treatment of Patients With RCC at Intermediate-High or High Risk of Recurrence Following Nephrectomy, or Following Nephrectomy and Resection of Metastatic Lesions
Keytruda Is the First Immunotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2021 Category: Drugs & Pharmacology Source Type: news
FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma
On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
What Is the Most Common Type of Renal Cell Carcinoma?
Title: What Is the Most Common Type of Renal Cell Carcinoma?Category: Diseases and ConditionsCreated: 11/5/2021 12:00:00 AMLast Editorial Review: 11/5/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 5, 2021 Category: Cancer & Oncology Source Type: news
Kidney cancer: The 8 signs of one of the most COMMON cancers in the UK
KIDNEY CANCER is the seventh most common cancer in the UK, so it's important to know the signs and symptoms to catch it early. (Source: Daily Express - Health)
Source: Daily Express - Health - October 28, 2021 Category: Consumer Health News Source Type: news
What Is Life Expectancy of Renal Cell Carcinoma
What Is the Life Expectancy of Someone with Renal Cell Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 27, 2021 Category: General Medicine Source Type: news
Kidney cancer: Two symptoms located on the back warning of the common cancer
KIDNEY cancer, or renal cell cancer, is one of the most common types of cancers in the UK. It usually affects adults in their 60s or 70s. (Source: Daily Express - Health)
Source: Daily Express - Health - October 22, 2021 Category: Consumer Health News Source Type: news
